> Home > Investors > Annual Review 2007 > Shareholder information
Shareholder information
Financial reporting
Financial reporting calendar 2008
| Announcement of 1st Quarter Results |
April 2008
|
|---|---|
| Announcement of 2nd Quarter Results |
July 2008
|
| Announcement of 3rd Quarter Results |
October 2008
|
| Preliminary Announcement of Annual Results |
February 2009
|
| Publication of Annual Report/Review |
February/March 2009
|
Results Announcements
Results Announcements are issued to the London Stock Exchange and are available on its news service. Shortly afterwards, they are issued to the media, are made available on the web site and are submitted to the US Securities and Exchange Commission and the New York Stock Exchange.
Financial reports
The company publishes an Annual Report and, for the investor not needing the full detail of the Report, an Annual Review. These are available on the web site. The Annual Review is sent to all shareholders. Shareholders may also elect to receive the Annual Report by writing to the company's registrars. Alternatively, shareholders may elect to receive notification by email of the publication of financial reports by registering on www.shareview.co.uk Copies of previous financial reports are available on the web site. Printed copies can be obtained from the registrar in the UK and from the GSK Response Center in the US.
Publications
In late March 2008 GSK will publish on the web site its Corporate Responsibility Report covering performance in areas including community investment, ethics and integrity, access to medicines, R&D, environment and health and safety.
Share price
|
2007
£ |
2006
£ |
2005
£ |
|
|---|---|---|---|
| At 1 January |
13.44
|
14.69
|
12.22
|
| High during the year |
14.93
|
15.77
|
15.44
|
| Low during the year |
11.60
|
13.26
|
11.75
|
| At 31 December |
12.79
|
13.44
|
14.69
|
| (Decrease)/increase |
(5)%
|
(9)%
|
20%
|
The table above sets out the middle market closing prices derived from the London Stock Exchange Daily Official List. The company's share price decreased by 5% in 2007 from a price of £13.44 at 1st January 2007 to £12.79 at 31st December 2007. This compares with an increase in the FTSE 100 index of 4% during the year. The share price on 22nd February 2008 was £11.10.
Market capitalisation
The market capitalisation of GSK at 31st December 2007 was £70 billion. At that date GSK was the fifth largest company by market capitalisation on the FTSE index.
Dividends
GSK pays dividends quarterly.
The Board has declared dividends for 2007 as follows:
| Dividends per share |
2007
pence |
2006
pence |
|---|---|---|
| First interim – paid 12th July 2007 |
12
|
11
|
| Second interim – paid 11th October 2007 |
12
|
11
|
| Third interim – paid 10th January 2008 |
13
|
12
|
| Fourth interim – payable 10th April 2008 |
16
|
14
|
| Total |
53
|
48
|
The table below sets out the dividends per ADS in US dollars in the last five years translated into US dollars at applicable exchange rates.
| Year |
US$
|
|---|---|
| 2007 |
2.14
|
| 2006 |
1.80
|
| 2005 |
1.57
|
| 2004 |
1.53
|
| 2003 |
1.39
|
Dividend calendar |
|
| Fourth quarter 2007 | |
| Ex-dividend date |
13th February 2008
|
| Record date |
15th February 2008
|
| Payable |
10th April 2008
|
| First quarter 2008 | |
| Ex-dividend date |
30th April 2008
|
| Record date |
2nd May 2008
|
| Payable |
10th July 2008
|
| Second quarter 2008 | |
| Ex-dividend date |
30th July 2008
|
| Record date |
1st August 2008
|
| Payable |
9th October 2008
|
| Third quarter 2008 | |
| Ex-dividend date |
29th October 2008
|
| Record date |
31st October 2008
|
| Payable |
8th January 2009
|
Annual General Meeting 2008
The Annual General Meeting will be held at the Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London SW1P 3EE on 21st May 2008.
Summary Directors' Report
The Performance overview, Business operating review, The Board, The Corporate Executive Team, Summary Remuneration Report, Corporate Governance, Responsibility statements and Shareholder information consist of summary financial information derived from the Report of the Directors in the Annual Report 2007 that has been drawn up and presented in accordance with, and in reliance upon, applicable English company law and the liabilities of the Directors in connection with that Report are subject to the limitations and restrictions provided by such law.
Notice regarding limitations on Director liability under English law
This Annual Review includes summary financial information derived from the Report of the Directors in the Annual Report 2007. Under the UK Companies Act 2006, a safe harbour limits the liability of Directors in respect of statements in and omissions from the Report of the Directors contained on pages 9 to 86 of the Annual Report 2007. Under English law the Directors would be liable to the company (but not to any third party) if the Report of the Directors contains errors as a result of recklessness or knowing misstatement or dishonest concealment of a material fact, but would not otherwise be liable.
Cautionary statement
Under the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward looking statements or projections made by the company, including those made in this Annual Review, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk factors' and 'Legal proceedings' in the company's Annual Report 2007.
The provision of the details on this page is not intended to be an invitation or inducement to engage in an investment activity. Advice on share dealing should be obtained from a stockbroker or independent financial adviser.
SmithKline Beecham plc Floating Rate Unsecured Loan Stock 1990/2010
The loan stock is not listed on any exchange but holders may require SmithKline Beecham plc to redeem their loan stock at par, i.e. £1 for every £1 of loan stock held, on the first business day of March, June, September and December. Holders wishing to redeem all or part of their loan stock should complete the notice on the back of their loan stock certificate and return it to the registrar, to arrive at least 30 days before the relevant redemption date.
Share buy-back programme
GSK has repurchased £11.6 billion of its own shares for cancellation or to be held as Treasury shares, of which £3.8 billion was spent in 2007. In July 2007 a programme totaling £12 billion of share repurchases over two years commenced. The programme covers purchases by the company of shares for cancellation or to be held as Treasury shares, in accordance with the authority given by shareholders at the AGM in 2007.
In May 2007, the company was authorised to purchase a maximum of 575 million shares. Details of shares purchased, those held as Treasury shares and those cancelled are disclosed in Note 33 to the financial statements, 'Share capital and share premium account' in the Annual Report 2007.
The exact amount and timing of future purchases, and the extent to which repurchased shares will be held as Treasury shares rather than being cancelled, will be determined by the company and is dependent on market conditions and other factors.
Share capital and control
Information in respect of section 992 of the Companies Act 2006 is given in the notes section of the company's Notice of Annual General Meeting.
Internet
Information about the company, including details of the share price, is available on GSK's web site at www.gsk.com.
Information made available on the web site does not constitute part of this Annual Review.
Trademarks
Brand names appearing in italics throughout this publication are
trademarks either owned by and/or licensed to GSK or associated
companies, with the exception of Boniva/Bonviva, a trademark of
Roche, and Entereg, a trademark of Adolor Corporation in the US,
which are used in certain countries under licence by the Group.
Investor relations
Investor Relations may be contacted as follows:
UK
980 Great West Road, Brentford, Middlesex TW8 9GS
Tel: +44 (0)20 8047 5000
US
One Franklin Plaza, PO Box 7929, Philadelphia PA 19101
Tel: 1 888 825 5249 (US toll free)
Tel: +1 215 751 4000 (outside US)
Ordinary shares
The company's shares are listed on the London Stock Exchange (LSE).
Registrar
The company's registrars are:
Equiniti
Aspect House, Spencer Way, Lancing, West Sussex BN99 6DA
www.shareview.co.uk
Tel: 0871 384 2991 inside the UK
Tel: +44 (0)121 415 7067 outside the UK
Equiniti also provide the following services:
• GlaxoSmithKline Investment Plan
• GlaxoSmithKline Individual Savings Account
• GlaxoSmithKline Corporate Sponsored Nominee
• Shareview service
• Shareview dealing service
• Dividend reinvestment plan
Shareview dealing service
Shareholders may buy or sell shares by internet or telephone through Shareview Dealing, a share dealing service provided by Equiniti. For internet purchases and sales log on to www.shareview.co.uk/dealing and for telephone purchases and sales call 0871 384 2020 (inside the UK only) between 8.00am and 4.30pm, Monday to Friday.
Glaxo Wellcome and SmithKline Beecham corporate PEPs
The Share Centre Limited
Oxford House, Oxford Road, Aylesbury, Bucks HP21 8SZ
Tel: +44 (0)1296 414 141
American Depositary Shares
The company's shares are listed on the New York Stock Exchange (NYSE) in the form of American Depositary Shares (ADSs) and these are evidenced by American Depositary Receipts (ADRs), each one of which represents two Ordinary shares.
In general, the NYSE's rules permit the company to follow UK corporate governance practices instead of those that apply in the US, provided that the company explains any significant variations. This explanation is provided on the company's website.
ADR programme administrator
The ADR programme is administered by:
The Bank of New York Mellon
Shareholder Relations
PO Box 11258, Church Street Station
New York NY 10286-1258
www.adrbny.com
Tel: 1 877 353 1154 (US toll free)
Tel: +1 212 815 3700 (outside US)
The administrators also provide Global BuyDIRECT, a direct ADS
purchase/sale and dividend reinvestment plan for ADR holders.
GSK Response Center
Tel: 1 888 825 5249 (US toll free)
Print-friendly
